MacuSight
Perceiva™
Perceiva™

Highlights of Phase 1 Perceiva Program

Data from MacuSight's Phase 1 trials of Perceiva have been presented at ophthalmology's most prestigious scientific and clinical meetings, including:

  • American Academy of Ophthalmology (AAO)
  • Association for Research in Vision and Ophthalmology (ARVO)
  • American Society of Retinal Specialists

Phase 1 Program Highlights
Overview Safety Results Biological Activity
  • Two simultaneous studies in DME and wet AMD
  • 80 patients total
  • Two administration routes: subconjunctival and intravitreal injection
  • Strong safety profile across all doses and routes of administration
  • No evidence of increased intraocular pressure, inflammatory response to treatment, or cataract progression
  • Improvements in visual acuity
  • Reductions in foveal retinal thickness

All findings were consistent across both subconjunctival and intravitreal routes, supporting Perceiva's unique administration advantages

"Two positive Phase 1 trials in 80 DME and wet AMD patients demonstrating key functional and anatomical improvements, as well as robust safety"